CUR vs. CLDI, PMCB, CHRO, BCLI, TSBX, BCDA, KLTO, ONVO, PALI, and ALBT
Should you be buying Neuralstem stock or one of its competitors? The main competitors of Neuralstem include Calidi Biotherapeutics (CLDI), PharmaCyte Biotech (PMCB), Chromocell Therapeutics (CHRO), Brainstorm Cell Therapeutics (BCLI), Turnstone Biologics (TSBX), BioCardia (BCDA), Klotho Neurosciences (KLTO), Organovo (ONVO), Palisade Bio (PALI), and Avalon GloboCare (ALBT). These companies are all part of the "medical" sector.
Neuralstem vs.
Neuralstem (NASDAQ:CUR) and Calidi Biotherapeutics (NYSE:CLDI) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, profitability, media sentiment, risk, valuation, institutional ownership, analyst recommendations, earnings and community ranking.
Calidi Biotherapeutics has a net margin of 0.00% compared to Neuralstem's net margin of -39,417.64%. Calidi Biotherapeutics' return on equity of 0.00% beat Neuralstem's return on equity.
Neuralstem received 278 more outperform votes than Calidi Biotherapeutics when rated by MarketBeat users.
38.3% of Neuralstem shares are held by institutional investors. Comparatively, 12.5% of Calidi Biotherapeutics shares are held by institutional investors. 5.4% of Neuralstem shares are held by company insiders. Comparatively, 24.3% of Calidi Biotherapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.
Neuralstem has higher revenue and earnings than Calidi Biotherapeutics.
In the previous week, Calidi Biotherapeutics' average media sentiment score of 0.95 beat Neuralstem's score of 0.00 indicating that Calidi Biotherapeutics is being referred to more favorably in the news media.
Calidi Biotherapeutics has a consensus price target of $16.67, suggesting a potential upside of 1,896.96%. Given Calidi Biotherapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Calidi Biotherapeutics is more favorable than Neuralstem.
Neuralstem has a beta of 1.81, suggesting that its stock price is 81% more volatile than the S&P 500. Comparatively, Calidi Biotherapeutics has a beta of 1.18, suggesting that its stock price is 18% more volatile than the S&P 500.
Summary
Calidi Biotherapeutics beats Neuralstem on 8 of the 14 factors compared between the two stocks.
Get Neuralstem News Delivered to You Automatically
Sign up to receive the latest news and ratings for CUR and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Neuralstem Competitors List
Related Companies and Tools
This page (NASDAQ:CUR) was last updated on 1/22/2025 by MarketBeat.com Staff
Free CUR Stock Alerts